PWZ-029 is a benzodiazepine derivative drug with nootropic effects developed by WiSys It acts as a subtype-selective mixed agonist-inverse agonist at the benzodiazepine binding site on the GABAA receptor acting as a partial inverse agonist at the α5 subtype and a weak partial agonist at the α3 subtype.
This page contains content from the copyrighted Wikipedia article "PWZ-029"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
